STOCKHOLM - 17 December 2025 - Reference is made to the stock exchange
announcement made by Inify Laboratories AB (the "Company") on 9 December 2025
regarding the fully guaranteed private placement of new shares in the Company
(the "Private Placement Shares") with gross proceeds of approximately NOK 92
million with a minimum subscription per subscriber of the NOK equivalent of EUR
100,000, directed pro-rata towards existing shareholders holding more than
1,000,000 shares in the Company (the "Private Placement"), and the fully
guaranteed repair issue of approximately NOK 8 million (the "Repair Issue"),
directed pro-rata towards existing shareholders that did not participate in the
Private Placement and who hold less than 1,000,000 shares in the Company. The
offer price per share in both the Private Placement and the Repair Issue is NOK
3.50 (the "Offer Price").
The application period for the Private Placement expired on 16 December 2025 at
16:30 hours (CET). Preliminary counting indicates that the Company has received
subscriptions for 25,759,315 Private Placement Shares, at the Offer Price. The
Private Placement Shares that are not allotted based on valid applications
received during the application period will be allocated to the guarantors
Monsun AS and Auris AS. The final results of the Private Placement are expected
to be announced on 19 December 2025.
The net proceeds from the Private Placement will be used to ensure financial
stability and persistence due to a slight delay in the fit-out project and
larger-than-expected investments related to the establishment in the UK.
Settlement
The date for payment of the Private Placement Shares is expected to be on or
about 25 March 2026 (the "Payment Date"). The new shares in the Private
Placement are expected to be delivered by 30 March 2026, subject to turnaround
time for registration of the share capital increase relating to the Private
Placement with the Swedish Companies Registration Office ("SCRO"). The shares
allocated in the Private Placement will be tradable on Euronext Growth Oslo when
the new shares have been registered with the SCRO and registered by Euroclear
Sweden and Euronext Securities Oslo ("VPS"), respectively, expected by 30 March
2026. The Company will announce when such registration has taken place.
Repair Issue
The Company will carry out the Repair Issue.
The Repair Issue will, subject to applicable securities law, be directed towards
all existing shareholders in the Company, other than the shareholders eligible
to take part in the Private Placement, as of 16 December 2025 (as registered in
VPS or Euroclear, as applicable, on 18 December 2025 (the "Record Date")), who
are not resident in a jurisdiction where such offering would be unlawful or
would (in jurisdictions other than Norway) require any prospectus, filing,
registration or similar action. Shareholders with shares registered with the VPS
as of the Record Date will receive non-tradable subscription rights to subscribe
for new shares in the Repair Issue. Shareholders with shares registered directly
with Euroclear as of the Record Date will not receive any subscription rights.
Instead, such shareholders will receive an application form which shall be used
to apply for subscription for shares in the Repair Issue. The application period
for the Repair Issue is expected to take place from on or around 12 January 2026
to 26 January 2026. Commencement of the application period will be announced in
a separate stock exchange notice.
Advisors
SB1 Markets AS ("SB1 Markets") has been appointed as financial advisor in
connection with the Private Placement and the Repair Issue. Schjødt law firm
acts as legal counsel to the Company.
For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker INIFY.
(https://live.euronext.com/en/product/equities/SE0017486103-MERK)
###
This information is subject to the disclosure requirements pursuant to section 5
-12 the Norwegian Securities Trading Act.
Important information
The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction.
This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and the Repair Issue must be made on the basis of all publicly
available information relating to the Company and the Company's shares. Such
information has not been independently verified by SB1 Markets. The information
contained in this announcement is for background purposes only and does not
purport to be full or complete. No reliance may be placed for any purpose on the
information contained in this announcement or its accuracy or completeness. SB1
Markets is acting for the Company in connection with the transaction and no one
else and will not be responsible to anyone other than the Company for providing
the protections afforded to its clients nor for giving advice in relation to the
transaction or any other matter referred to herein.
This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and the Repair Issue.
Each investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.
The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Norwegian law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.
No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.
Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.
In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order")